Previous Close | 27.65 |
Open | 27.75 |
Bid | 27.53 x 3200 |
Ask | 27.55 x 4000 |
Day's Range | 27.43 - 28.22 |
52 Week Range | 25.20 - 39.87 |
Volume | |
Avg. Volume | 38,097,892 |
Market Cap | 156.001B |
Beta (5Y Monthly) | 0.64 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.05 |
Earnings Date | Jul 30, 2024 - Aug 05, 2024 |
Forward Dividend & Yield | 1.68 (6.10%) |
Ex-Dividend Date | May 09, 2024 |
1y Target Est | 31.46 |
Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID-19 vaccine achieved non-inferior vaccine efficacy against COVID-19 when compared with its previously approved bivalent COVID-19 vaccine.
An FDA panel endorses Eli Lilly's (LLY) Alzheimer's disease drug, donanemab. Pfizer's (PFE) DMD study on investigational gene therapy fails.
NEW YORK, June 14, 2024--Pfizer Inc. (NYSE: PFE) today announced detailed overall survival (OS) results from the Phase 2 MagnetisMM-3 study of ELREXFIO™ (elranatamab-bcmm) in patients with heavily pretreated relapsed or refractory multiple myeloma (RRMM). The study demonstrated a median OS of 24.6 (95% CI, 13.4, NE) months in cohort A (n=123) of the pivotal single arm trial.